Index

Note: Page numbers of article titles are in **bold face** type.

A, B, H, Le^a and Le^b substances, 29–31
Abetalipoproteinaemia, 22
Acidified-serum test, 216–218
Anaemia—
  autoimmune haemolytic, **167–179**
  congenital nonspherocytic haemolytic, 88–95
  drug-induced haemolytic, **181–194**
  haemolytic, *see* Haemolytic anaemia
  high phosphatidylcholine haemolytic, 22
  immune haemolytic, 75–76
  laboratory evaluation of haemolytic, 132–134
  malaria and, 247–249
  microangiopathic haemolytic, 77
Anaemia and jaundice in the newborn, causes of, 159–161
Androgens, in paroxysmal nocturnal haemoglobinuria, 222
Antibodies, warm and cold, 41–42
Antibody, serum, screening of in haemolytic anaemia, 189–191
Antibody and antigens, the reaction between, 32–42
Antibody concentration, equilibrium constant and the formation of, 39–41
Antibody titre, 153–154
Anticoagulants, in paroxysmal nocturnal haemoglobinuria, 222
Antigen–antibody bond, 32
Antigen–antibody reactions, 32–37
  effect of ionic strength on, 38–39
  equilibrium constant, 35–36
  rate of association, 34
  rate of dissociation, 34–35
Antigens on the red-cell surface, 29–32
Antiglobulin test, direct, in drug-induced haemolytic anaemia, 189

BLOOD volume, the spleen and, 239–240
Bone marrow, and paroxysmal nocturnal haemoglobinuria, 214

COAGULATION, malaria and, 250–251
Cold-antibody haemolysis test, 215–216
Corticosteroid therapy—
  in immune haemolytic disease, 174–175
  in paroxysmal nocturnal haemoglobinuria, 221–222

DEXTRAN solutions, in paroxysmal nocturnal haemoglobinuria, 221
2, 3-diphosphoglycerate mutase deficiency, 54–55
Discocyte changes, mechanisms of, 8–10
Discocyte–echinocyte transformation, 6–8
Discocyte–stomacyte transformation, 8
Drugs, immune response to, 181–189

ELECTROPHORESIS, haemoglobin, 75
Elliptocytosis, 15
  hereditary, 58
Endovesiculation, 11–12
Enzyme abnormalities—
  classification of, 129–130
  in paroxysmal nocturnal haemoglobinuria, 200
  quantitative, 94–95
Epiphysial fusion, and sickle cell disease, 115
Equilibrium constant, 35–36
  biological significance of, 36–37
Erythrocyte shape, progression of reversible to irreversible alterations, 10–12
Erythrocytes—
  ageing of, 52
  microspherulation and loss of myelin forms, 10–11
Exchange transfusion, technique of, 151

GLYCOLYSIS, 46–48
  enzyme deficiencies in, 53–56
  function of red-cell, 125–126
  regulation of, 48–49
Glycolytic enzymopathies—
  clinical presentation, 131–132
  therapy for, 134–135
Glucose phosphate isomerase deficiency, 53

Glucose-6-phosphate dehydrogenase deficiency, **83–102**
expression of in heterozygotes, 100–101
genetic aspects, 97–101
genetic interactions, 100
leucocytes and, 95–96
malaria haemoglobins and, 252–253
special clinical interactions of, 96–97
variability in human populations, 97–99
Glutathione deficiency, 192
Glutathione metabolism, 50
enzyme deficiencies in, 56–57
Glutathione reductase deficiency, 192

HAEMATOLOGICAL aspects of malaria, **247–253**
Haematology—
of paroxysmal nocturnal haemoglobinuria, 212–214
sickling and, 112–113
Haemoglobinaemia, 69
Haemoglobinopathies, tests for, 74–75
Haemoglobins—
abnormalities of, 16–20
depletion of plasma, 69
detection of unstable, 75
unstable, 193
Haemoglobinuria, 69
acute and chronic, 76–77
paroxysmal nocturnal, **199–223**
causes of death, 211
clinical diagnosis, 211–212
clinical features, 204–205
course of, 209–211
evolution of, 210
laboratory diagnosis, 214–220
laboratory features, 212–214
pathogenesis, 203–204
perspective in therapy, 223
red-cell abnormality, 199–203
serological tests, 215–220
symptoms, 205–209
therapy, 220–223
Haemolysis—
diagnosis of oxidative, 193–194
due to pyruvate kinase deficiency and other glycolytic enzymopathies, **123–144**
features of intravascular, 69
in paroxysmal nocturnal haemoglobinuria, 205–207
mechanics of, 93–94, 126–129
membrane structure and its relation to, **3–23**
radioisotopic investigation of, 240–241
tests that define the cause of, 73–78
Haemolytic anaemia—
autoimmune, **167–179**
Haemolytic anaemia *(continued)*
clinical and laboratory evaluation of suspected drug-induced, 189–191
congenital nonspherocytic, 88–95
drug-induced, **181–194**
laboratory evaluation of, 132–134
nonimmunological drug-induced, 191–194
with haemoglobinuria, 76–77
Haemolytic anaemia in the newborn infant, **145–161**
clinical features, 148
due to blood group incompatibility, 146–155
long-term follow-up, 156
management of severe, 151
treatment, 148–150
Haemolytic disorders—
splenectomy in, 241–243
the spleen and, **231–243**
(*see also* Immune haemolytic disease)
Haemolytic states—
compensatory mechanisms, 72–73
diagnosis of, **63–78**
indications of increased red-cell destruction and compensatory mechanisms 68–72
patient's history, 65–66
peripheral blood smear, 67–68
physical examination, 67
inherited: glucose-6-phosphate dehydrogenase deficiency, **83–102**
public health aspects, 85–88
metabolism in, **45–59**
Haemopexin, 69–70
Haemorrhage, in newborn infants, 157
Haemosiderinuria, 69
Heat-resistance test, 215
Heinz bodies, 72
Heinz body disorders, 18–20
Hepatitis, viral, 97
Hexokinase deficiency, 53
Hexose monophosphate pathway, 49–50
Hyperbilirubinaemia, 68
management of, 150–151
Hyperplasia, bone-marrow erythroid, 73
Hypersplenism, 77–78, 234–235
Hypoglycaemia, 151–152
Hypoplasia, bone-marrow, in paroxysmal nocturnal haemoglobinuria, 208

IMMUNE haemolytic disease: the autoimmune haemolytic anaemias, **167–179**
age distribution, 170–171
classification, 167–168
clinical aspects, 170–173
general considerations, 167–170
genetic predisposition, 168–169

Immune haemolytic disease *(continued)*
immunosupparessive therapy, 175
incidence, 170
presenting symptoms and signs, 171–172
race, sex and, 171
significant associated diseases, 168
survival and prognosis, 172–173
theoretical concepts, 169–170
therapeutic aspects, 173–178
treatment of associated diseases, 173–174
Induction, premature, 155
Infections, in paroxysmal nocturnal haemoglobinuria, 208–209
Ion permeability and/or transport, altered, 12–13
Iron, in paroxysmal nocturnal haemoglobinuria, 222

JAUNDICE, 68

LECITHIN-cholesterol acyl tranferase deficiency, plasma, 22
Lipid composition, alterations in membrane, 20–22
Liquor examination, 154–155
Liver disease—
obstructive, 22
Zieve's syndrome, 22

MALARIA—
and anaemia, 247–249
and coagulation, 250–251
and splenomegaly, 251–252
and white cells, 249–250
haematological aspects of, **247–253**
Malaria haemoglobins, and glucose-6-phosphate dehydrogenase, 252–253
Membrane abnormalities secondary to intracellular or extracellular factors, 16–22
Membrane disorders, primary, 14–16
Membrane shape and deformability, altered, 13–22
Membrane structure—
and its relation to haemolysis, **3–23**
reversible changes in, 5–10
Membranes, ultrastructure and chemical composition of normal erythrocyte, 3–5
Metabolic abnormalities, in nonimmunological drug-induced haemolytic anaemia, 191–192
Metabolism—
enzyme deficiencies in glutathione, 56–57
glucathione, 50
in haemolytic states, **45–59**
Metabolism *(continued)*
nucleotide, 50–51
red-blood cell, 123–125
Methaemalbumen, 69
Methaemoglobinaemia, 72
Morphological abnormalities in paroxysmal nocturnal haemoglobinuria, 200–203

NUCLEOTIDE metabolism, 50–51

PHOSPHOFRUCTOKINASE deficiency, 54
Phosphogluconic dehydrogenase deficiency, 192–193
Phosphoglycerate kinase deficiency, 54
Phototherapy, 150
Pneumonia, lobar, 96
Pyruvate kinase deficiency, 55

RADIOISOTOPIC investigation of haemolysis, 240–241
Red blood cell metabolism, 123–125
Red cell, effect of the spleen on the, 238–239
Red-cell abnormality, in paroxysmal nocturnal haemoglobinuria, 199–203
Red-cell antibodies induced by drugs, 187–189
Red-cell antigens, antibodies and their interaction, **29–42**
Red-cell damage, manifestations of, 71–72
Red-cell destruction, sites of, 71
Red-cell eluate, testing of, 191
Red-cell enzyme defects, hereditary, 74
Red-cell fragmentation, 72
Red-cell glycolysis, function of, 125–126
Red cell life span, shortened, 70–71
Red cell membrane, modification of by drug allowing nonimmunological adsorption of protein, 185–187
Red cell surface, number of available antigen sites on, 31–32
Red cells—
drug adsorbed on to, 183–185
effect of enzyme treatment of, 37–38
immune-complex adsorption to, 183
increased osmotic fragility of, 72
Renal failure, acute, 97
Reticulocyte count, 72–73
Reticulocyte production index, 72–73
Rh isoimmunisation, prevention of, 156–158

SALMONELLOSIS, 96
Serological abnormalities, in paroxysmal nocturnal haemoglobinuria, 199–200
Sickle cell disease, 16–18

Sickle cell disease *(continued)*
abnormal habitus in, 115
clinical significance of Hb F levels, 112–115
continuation of fetal haemoglobin synthesis in, 118–119
factors affecting Hb F level in, 117–118
fetal haemoglobin in homozygous, **109–120**
historical observations, 109–110
persistence of Hb F in, 109–110
relation of Hb F to the sickling process, 110–112
role of Hb F in modifying clinical severity of, 115–117
Sickled cells, irreversibly, and Hb F, 110–111
Sickling—
demonstration of, 74–75
gelation studies, 110
in vivo and in vitro observations on Hb F and, 111–112
Spherocytosis, 71–72
Spherocytosis, hereditary, 14–15, 57–58, 75, **139–144**
laboratory findings, 140–141
pathogenesis, 142
role of spleen in, 142–144
treatment, 141–142
Spleen—
and blood volume, 239–240
and haemolytic disorders, **231–243**
effect of on the red cell, 238–239
functions of the, 232–234
red-cell pooling, 236–238
role in haemolytic anaemia, 94
vascular architecture of the, 235–236
Splenectomy—
in haemolytic disorders, 241–243
for autoimmune haemolytic anaemia, 176
Splenomegaly, malaria and, 251–252
Stillbirth, prevention of, 152–153, 155–156
Stomacytosis, 16
Sucrose-haemolysis test, 218–220

THALASSAEMIA, tests for, 74–75
Thrombin test, 216
Thrombosis, in paroxysmal nocturnal haemoglobinuria, 207–208
Tissue infarction, in sickle cell disease, 113–115
Transfusion—
blood, in autoimmune haemolytic anaemia, 176–177
blood, in paroxysmal nocturnal haemoglobinuria, 220–221
intra-uterine, 155
Triose phosphate isomerase deficiency, 54

UROBILINOGEN, increased urinary and faecal, 68

VESSEL obstruction, in sickle cell disease, 113

WHITE cells, malaria and, 249–250

ZIEVE's syndrome, 22

NDEX

a, 176
156

urnal
sease,

anae-
emo-

54

aecal,

e, 113

Index

Note: Page numbers of article titles are in **boldface** type.

ADJUVENT treatment in polycythaemia vera, 454
Anaemias, and myelofibrosis, 325
Animals, myeloproliferative disorders in, 457–458
Argyrophilic fibres, amount of in bone marrow, 331–333
Arterial oxygen content, measurement of, 271

BENZENE, injection of in animals, 462
Bleeding time, and platelet function, 387
Blood viscosity, in polycythaemia vera, 354–355
Blood volume, measurements in polycythaemia vera, 265, 267–268
Bone marrow—
  morphological features of in polycythaemia vera, 273–274
  patho-anatomical features of the, **331–350**
Bone marrow distribution, in polycythaemia vera, 274
Bone marrow scanning and quantitation in myelofibrosis, 420
Bone marrow supporting stroma, involvement of, 279
Busulphan, 446–447

CARCINOMA, and myelofibrosis, 324–325
Chemotherapeutic agents, in polycythaemia vera, 445–447
Chemotherapy, miscellaneous agents, 447
Chlorambucil, 446
Chromosomal findings in leukaemia, 430
Cirrhosis of the liver, myelofibrosis and, 303
Counting, use of surface, in myelofibrosis, 417–420
Cyclophosphamide, 447
Cytological methods and specimens employed in diagnosing polycythaemia vera and myelofibrosis, 310–311

DRUGS, injection of cytostatic, in animals, 462

EOSINOPHILIC fibrohistiocytic lesion, and myelofibrosis, 346
Erythrocyte pooling, splenic, 401
Erythrocytes, in polycythaemia vera, 354
Erythrocytosis, evaluation of, 268–272
Erythrocytosis and polycythaemia vera, differential diagnosis of, 335–336
Erythrokinetics, in polycythaemia vera, 414–415
Erythropoiesis—
  extramedullary, causation and significance of, 423–424
  extramedullary splenic, 400–401
  sites of, in polycythaemia vera, 412–414
Erythropoietin elaboration—
  assessment of, 272
  inappropriate increase in, 272–273
Erythropoietin production, assessment of, 272–273
Erythropoietin-erythroid stem cell axis, assessment of, 269, 271–272

'FIBRIN-fasersterne', 346–349

'HAEMOPOIETIC organ' involvement, total, 273–275
Hepatomegaly, in erythrocytosis, 275
Hormones, induction of, in animals, 465–466
Hyperhaemolysis, splenic, 401

IONIZING radiation, and myelofibrosis, 463–465
Iron kinetics, **407–424**
  patterns of in myelofibrosis, 420–422

LEAD acetate, injection of in animals, 462–463
Leucocytes—
  in myelofibrosis, 364–366
  in polycythaemia vera, 362–364
Leukaemia—
  and myeloid metaplasia, relationship between, 434–435

Leukaemia—*continued*
and patient with polycythaemia vera, 436
and polycythaemia vera, relationship between, 427–432
cell type, 431
radiation therapy and, 428–429
Leukaemia, acute myeloid—
and myelofibrosis, 346
transformation of polycythaemia vera into, 338
Leukaemia, chronic myeloid—
and myelofibrosis, 345–346
and polycythaemia vera, differential diagnosis, 336
Liver and spleen, patho-anatomical features of the, **309–328**
Lymphomas, malignant, in myelofibrosis, 323–324

MARROW, toxic necrosis of the, 460–463
Melphalan, 446
Myelofibrosis—
and cirrhosis of the liver, 303
atypical forms of, 301–303
biochemical alterations in, 257
blood findings in, 293–294
bone marrow findings, 295–296
cellular phase of, 336, 338–339
chromosome studies of, 297–298
clinical course, 303–305
clinical symptoms, 291–293
course of the disease, 344
definition, clinical features and diagnosis of, **291–305**
diagnosis, 291–299
diagnosis of myeloid metaplasia, 322–327
differential diagnosis, 299–300, 344–346
'early' and 'mild', 326–327
experimental, **457–475**
extramedullary tumorous forms, 303
haemostasis, abnormalities of, 294–295
half disappearance time, 415
in other neoplasms of the bone marrow, 349
induced by experimental infarctions, 458–459
leucocyte alkaline phosphatase in, 296–297
miscellaneous laboratory findings, 298
patho-anatomical features of, 338–346
radiological bone findings, 299
the liver in, 321
the spleen in, 313–321
value of iron kinetics in, 424
virus-induced, 466–467
with osteosclerosis, 339–40, 343–344
without osteosclerosis, 339
Myeloid leukaemia, chronic, 322–323
Myeloid metaplasia—
and leukaemia, relationship between, 434–435
and myeloid fibrosis, 322–327
and polycythaemia vera, relationship between, 432–434
radiation therapy and, 433
Myeloma, multiple, in myelofibrosis, 324
Myeloproliferative syndrome, platelets in the, **373–389**
Myelosuppressive therapy, 445–447

OXYGEN delivery, assessment of, 271–272

PAN-MYELOPATHY, and myelofibrosis, 346
Peripheral blood, in polycythaemia and myelofibrosis, **353–369**
Peripheral blood manifestations—
of basophil involvement, 278–279
of erythropoietic involvement, 275
of granulocytic involvement, 276–278
of megakaryocytic involvement, 275–276
Peripheral platelet count, 374
Phlebotomy, and polycythaemia vera, 443–444
Plasma clearance of iron, in polycythaemia vera, 409–410
Plasma iron turnover—
in myelofibrosis, 415–416
in polycythaemia vera, 410–412
Plasma volume—
expansion of the total, 401–404
total, 395
Platelet adhesiveness, 388
Platelet aggregation, 387–388
Platelet defects, quantitative, 386–389
Platelet factor 3 activity, 388–389
Platelet number, total body, 378–380
Platelet pool, distribution of platelets and the exchangeable, 375–378
Platelet production, 382–384
Platelet size and ultrastructure, 384–386
Platelet survival, 380–382
Platelets—
distribution of, and exchangeable splenic platelet pool, 375–378
in myelofibrosis, 367–368
in polycythaemia, 366–367
in the myeloproliferative syndrome, **373–389**
Poikilocytes, fate and origin of, in myelofibrosis, 359–362
Polycythaemia vera—
aetiology, 263–264
and leukaemia, relationship between, 427–432
and myeloid metaplasia, relationship between, 432–434

clinical aspects of, 279–287
clinical features and complications:
due to basophil proliferation, 283
due to granulocytic involvement, 282–283
due to increased cell turnover, 286–287
due to involvement of erythrocytes and platelets, 279–282
due to myeloid metaplasia, myelofibrosis and osteosclerosis, 285–286
course of the disease, 336–338
definition, clinical features and diagnosis of, **263–287**
diagnostic features of, 273–279
differential diagnosis, 335–336
effects of therapy, 336–337
epidemiology and host factors, 279
guidelines for management of patients, 455–456
myelosuppression therapy, 445–447
patho-anatomical features of, 333–338
plasma clearance of iron in, 409–410
principles of management, 442–443
prognosis and survival, 287
'spent' phase of, 454–455
the liver in, 313
the spleen in, 311–313
transition into myelofibrosis, 337–338
treatment of, **441–456**
value of iron kinetics in, 424
what it constitutes, 264–265
Polycythaemia vera and myelofibrosis, the peripheral blood in, **353–369**
Polycythaemia, leukaemia and myeloid metaplasia, interrelationship between, **427–436**
Polycythaemia Vera Study Group, 447–454
Polycythaemic patient, initial evaluation of the, 265–273
Protein, injection of foreign, in animals, 467–472

RADIATION, ionising, and myelofibrosis, 463–465
Radioactive phosphorus, and polycythaemia vera, 445
Red cell kinetics, **393–404**
Red cell morphology—
in myelofibrosis, 356–359
in polycythaemia vera, 355–356
Red cell pooling in enlarged spleens, 395–398
Red cell production, in polycythaemia vera, 412
Red cell production and destruction, general assessment of, 394
Red cell sequestration (destruction) in enlarged spleens, 398–400
Red cell utilisation of iron, in myelofibrosis, 416
Red cell volume—
in polycythaemia vera, 354
total, 394

SAPONIN, injection of in animals, 460–462
Screening, for polycythaemia vera, 265, 266
Spleen, as filter, in myelofibrosis, 366
Spleen and liver, patho-anatomical features of the, **309–328**
Spleens, enlarged—
red cell pooling in, 395–398
red cell sequestration (destruction) in, 398–400
Splenectomy, in myelofibrosis, 327
Splenomegaly, in erythrocytosis, 274–275

THROMBOCYTHAEMIA and polycythaemia vera, differential diagnosis, 336
Thrombocytopenia and myelofibrosis, 346
Trauma, mechanical, in experimental myelofibrosis, 459–460
Tuberculosis, and myelofibrosis, 323

WHITE cell morphology, in myelofibrosis, 364–365

Index

Note: Page numbers of article titles are in **bold face** type.

AGRANULOCYTOSIS, infantile genetic, or congenital neutropenia, 562
Alder–Reilley anomaly, 499–500
Aleukia, congenital, or reticular dysgenesia, 561–562
Antigen processing, macrophages and, 692–694
Antimicrobial defence function of mononuclear phagocytes, 689–691
Auer body, 498–499

BACTERIA, disorders due to diminished ingestion of, 622–623
Bacterial killing, 643
Basophil chemotaxis, 670–671
Basophil degranulation, a general model of, 675–677
Basophil frequency, normal, 652
Basophil frequency and distribution, physiological and pathological variations in, 652–654
Basophil hypersensitivity, cutaneous, 665–668
Basophilic leucocytes: structure, function and role in disease, **651–677**
Basophils, 578
  acid mucopolysaccharides, 660
  biochemical contents of, 658–661
  histamine and histamine synthesising capacity, 659–660
  in delayed-type reactions in man, 668–670
  mature human, 654–656
  morphology, 654–658
  other than human, 656–658
  participating in cell-mediated hypersensitivity reactions, degranulation of, 673–675
  phagocytosis and pinocytosis, 671
  platelet activating factor, 660–661
  various constituents of, 661
Blood and tissue eosinophilia, mechanisms of, 644–645
Blood neutrophil concentration—
  decreased blood neutrophil concentration and decreased cell production, disorders usually characterised by, 561–564
Blood neutrophil concentration (*continued*)
  elevated, or increased cell production, disorders usually characterised by, 553–561
Blood neutrophil kinetics, 538–540
Bone marrow, differentiation of basophils in the, 658

CATIONS, divalent, and chemotaxis, 581–582
Cell adherence, 579
  abnormal, 590–591
Cell culture methods, 512–516
  methodological problems and pitfalls, 515–516
Cell deformability, abnormal, 591–592
Cell migration—
  abnormal directed, 593
  abnormal random, 592–593
Cell serine esterases, activation of by chemotactic factors, 580–581
Cell surface, interaction of chemotactic factors with, 579–580
Cell-derived activators of the complement system, 573–574
Cell-derived chemotactic factors, 572–573, 588
Cell-derived inactivators, a potential abnormality, 589
Cell-derived products, 572–574
Cell-specific chemotactic attraction, mechanism of, 578–579
Cells, colony-stimulating activity-producing, 521–522
Cells of body, phagocyte, 610
Cellular defects, 589–595
Cellular immunity, macrophages and, 694–695
Cellular interactions in normal granulopoiesis in culture, 516–522
Chalone, 545–547
Chediak–Higashi–Steinbrinck syndrome, 497
Chemoattractants, 570–575
Chemotactic activity—
  in products of bacterial growth and viral infected tissues, 575

Chemotactic activity (*continued*)
of collagen, chemically altered proteins, and sodium caseinate, 574
Chemotactic defects, unclassified, 594–595
Chemotactic factor formation and function, inhibition of, 588
Chemotactic factor inactivators and inhibitors of cell motility, 575–577
Chemotactic factors—
abnormal, 586–589
defective inactivation of, 588–589
inhibitors of the, 576
Chemotactic response, enzymes and metabolic pathways in, 582–583
Chemotaxis—
abnormal, 586–595
disorders of, therapeutic possibilities, 595–596
of eosinophils, lymphocytes and basophils, 577–579
Chemotaxis in vivo, 584–586
Colony methods of cell culture, 512–513
Colony-stimulating activity (CSA), 521, 545
Complement defects, 586–587
Complement pathway, 570–571

DEBRIS, removal of by monocyte-macrophage phagocytic mechanism, 691
Degranulation, 614–615, 643, 672–677
IgE-mediated anaphylactic, 672–673

EOSINOPHIL cytogenesis, 638–640
Eosinophil function, 640–645
Eosinophil leucocytes: structure and function, **635–645**
Eosinophils, 577
histochemistry and enzyme analysis, 637–638
morphology, 635–638
motility and chemotaxis, 640
ultrastructure, 635–636
Erythropoiesis, control of granulopoiesis and involvement in, 695–696

FIBRINOLYTIC and kinin-generating systems, 571–572

GAUCHER'S disease, 715
Generation of chemotactic factors, 586–588
Granule formation and degranulation, disorders of, 623–625
Granules—
'physiological' alterations in, and other inclusions, 492
Granules (*continued*)
ultrastructure of polymorphonuclear, 489–492
Granules and inclusions, pathological, 497–500
Granuloma, eosinophilic, 713–714
Granulopoiesis, control of, and involvement of monocytes and macrophages in, 695–696
Granulopoiesis in culture—
cellular interactions in normal, 515–522
model of membrane-mediated regulation of, 522
of cells from patients with leukaemia, 522–527
of human haemopoietic cells, **509–529**
Granulopoietic colony-stimulating activity in leukaemia, 525–526
Granulopoietic progenitors capable of forming colonies in culture, 518–520
Granulopoietic substance, diffusable, 545

HAEMOLYTIC anaemia, 707–708
Haemopoietic cells, granulopoiesis in cultures of human, **509–529**
Haemopoietic system, organisation in, 510–512
Hand–Schüller–Christian disease, 713
Histamine release, mechanism of IgE-mediated, 663–665
Histiocytic disorders, malignant, 226–231
Histiocytic lymphoma, 710–711
Histiocytic medullary reticulosis, 711
Histiocytoses, idiopathic, 712–713
Histiocytosis, sea-blue, 715–716
Hyperplasia, reactive, 705–708

IMMUNE adherence, 611–612
Immune response, function of monocyte phagocytes in, 691–695
Immunoglobulin in E, 661–663
Ingestion, 612–614
Intraleucocyte microbicidal activity, disorders associated with impaired, 625–628

KINETICS—
blood neutrophil, 538–540
of neutrophils entering inflammatory exudates, 535–538
Kinin-generating systems—
abnormal, 587–588
fibrinolytic and, 571–572

LAZY leucocyte syndrome, 563

Letterer–Siwe disease, 711
Leucocyte, inhibitors acting on the, 576–577
Leucocyte chemotaxis: physiological considerations and abnormalities, **567–596**
Leucocyte function lacking morphological counterparts, disorders of, 500–501
Leucocyte locomotion, assay of, 567–570
Leucocyte structural elements and chemotaxis, 583–584
Leucocytes—
basophilic: structure, function and role in disease, **651–677**
eosinophilic: structure and function, **635–645**
physiology of the interaction of, with chemotactic factors, 579–584
Leukaemia—
granulopoiesis in cultures of cells from patients with, 522–527
hairy-cell, 712
monocytic, 708–710
Leukaemoid reactions, 559–560
Lymphocytes, 577–578

MACROPHAGE—
antitumour activity of, 695
tissue, 686–687
Macrophage dysfunction syndromes, 716–717
Macrophages, morphological alterations in monocytes and, 501–504
Marrow storage pool, 543
May–Hegglin anomaly, 497–498
Metabolism, stimulation of oxidation, 615–618
Microbe ingestion and killing by neutrophils: normal mechanisms and abnormalities, **609–628**
Microbial ingestion, 610–618
Microbicidal mechanisms, 618–621
Molecular species with colony-stimulating activity, 520–521
Monoblast, 685–686
Monocyte, blood, 686
Monocyte function, 689–696
Monocyte kinetics, 687–688
Monocyte metabolism, 688–689
Monocytes, physiological and pathological variations in the ultrastructure of neutrophils and, 485–504
Monocytes and macrophages, morphological alterations in, 501–504
Monocytosis, 708
Mononuclear phagocyte proliferation, maturation, and function, **685–696**
disorders of, **705–717**
Myeloblastic leukaemia, acute, 560–561
Myelocytic leukaemia, chronic, 553–557
Myelofibrosis, idiopathic, 558–559
Myelokathexis, 563

NEUTROPENIA—
chronic, 528
cyclic, 527–528, 562–563
Neutrophil, nucleus of, 486–489
Neutrophil production, 540–543
Neutrophil proliferation and circulation: disorders of, **553–564**
Neutrophil proliferation, maturation and circulation, phsyiology of, **535–547**
Neutrophil releasing factor, 544–545
Neutrophilia, hereditary, 560
Neutrophilic system, control of the, 543–547
Neutrophils, microbe ingestion and killing by, **609–628**
Neutrophils and monocytes, physiological and pathological variation in the ultrastructure of, **485–504**
Niemann–Pick disease, 715
Nucleotides, cyclic, and leucocyte migration, 582

OPSONISATION, 611
disorders of, 621–622
Oxidation metabolism, stimulation of, 615–618
Oxygen-dependent microbial mechanisms, 618–620
Oxygen-independent microbial mechanisms, 620–621

PHAGOCYTE proliferation, maturation and function, mononuclear, **685–696**
Phagocytic function, disorders of, 621–628
Phagocytosis, 642
and pinocytosis, 671
Polycythaemia rubra vera, 557–558
Preleukaemia and neutropenic states, 527–528
Promonocyte, 686

RETICULOENDOTHELIOSIS, leukaemic, 712
Reticulosis, histiocyte medullary, 711
Reticulum cell sarcoma, 710–711

SERUM inactivators, 588–589
Serum inhibitors that act directly on the cell, 589
Sickle cell disease, 621–622
Storage diseases, 714–716
Suspension culture methods, 513–515